

Proper Management of Cyclic Vomiting Syndrome

¹Bassam Awad M Alzubaidi, ²Sultan Thayer N Alharbi, ³Nasser Abdullah N Aldawsari

Abstract: The objectives of this review are to identify the clinical features that suggest a diagnosis of CVS and to review the literature on its management. Relevant studies were identified by a search of electronic databases, including MEDLINE, EMBASE, for all these articles published from time of instance up to December 2017, in English language and discussing cyclic vomiting syndrome management and diagnostic approaches, containing human subjects only. CVS is an idiopathic functional vomiting disorder at first defined in kids that is increasingly recognized in grownups. Although documented pathophysiologic associations with migraine, mitochondrial conditions, and neuroendocrine abnormalities have been described in pediatric CVS, migraines, anxiety, and panic appear to be typical associations in adults that need further study. The natural history of CVS in children suggests that the majority of will outgrow this debilitating disorder with time, though some will transition to migraine headaches and even continue to suffer CVS as adults. Current therapy for CVS can be divided into supportive therapy (during episodes), prophylactic therapy (to avoid episodes), and abortive treatment (to prevent development from prodromal symptoms to the vomiting phase). Strategies for management of CVS during the interepisodic duration consist of avoidance of determined triggers, lifestyle modifications, and psychological interventions.

Keywords: cyclic vomiting syndrome (CVS), supportive therapy.

1. INTRODUCTION

Vomiting or abdominal pain makes up 10% of sees to the emergency department, and vomiting is the third most common factor for a youngster being seen [1,2]. For a lot of these patients, the diagnosis will not remain in doubt but cyclic vomiting syndrome (CVS) is a rare and regularly undiagnosed condition that has historically been extremely improperly diagnosed and treated in the emergency situation division. CVS is an idiopathic chronic condition identified by frequent episodes of vomiting and nausea divided by reasonably asymptomatic durations. The diagnosis is typically postponed and usually it takes a mean of 15 emergency department visits [3] or B6 years prior to a medical diagnosis is made [4], with patients often classified as showing 'drugseeking behavior'.

The aetiology of CVS is not recognized, however it is possibly because of a dysregulation of the neuroendocrine system. Irregular vagal inflection of the heart has been defined in patients [5] with tachygastria noted on electrogastrography [6]. CVS is related to migraines. A typical pathophysiological process is postulated as some patients frequently report photophobia and a prodrome prior to the strikes [7]. The strong organization in between CVS and mother's migraine [8] has spurred research right into the opportunity of maternal inheritance of mitochondrial illness. CVS has been related to a number of mitochondrial DNA polymorphisms including 19519C -->T [9] and versions in the hypervariable sectors in the mitochondrial series [10].

The objectives of this review are to identify the clinical features that suggest a diagnosis of CVS and to review the literature on its management.

2. METHODOLOGY

Relevant studies were identified by a search of electronic databases, including MEDLINE, EMBASE, for all these articles published from time of instance up to December 2017, in English language and discussing cyclic vomiting syndrome management and diagnostic approaches, containing human subjects only. Search terms were used to identified articles as

following: “cyclic vomiting syndrome” and “management” and treatment. furthermore, references list of identified studies were searched for more relevant identical studies.

3. DISCUSSION

• Clinical Features and Symptoms:

CVS is differentiated by distinct, reoccurring, and serious episodes of vomiting. Stereotypy of episodes in relation to time of onset, period, and symptomatology is a regular finding in both kids and grownups with CVS. In kids, an on-off pattern with periods of going back to complete normalcy or baseline health and wellness between episodes is most typical [11]. Interepisodic signs of queasiness and throwing up have been reported in 50-63% of adult patients [12]. Low-grade, baseline abdominal pain and nausea tantamount from useful dyspepsia is additionally a typical attribute in adults, often precipitated by stress and anxiety [13]. The period of the episode generally varies from hours to days, with a mean duration of 27 hours in children and 3-6 days in grownups [14]. The median frequency of episodes is 4 weeks in children and 3 months in adults [14], [15]. One of the most typical time of start in all age teams is nighttime or morning, with many patients experiencing start from 1 AM to 7 AM [16]. Among children with CVS, 67% have a well-described prodrome, with an average duration of 0.5-1.5 hrs that precedes the vomiting episodes as compared to 93% in one adult collection of 41 patients [12]. In spite of the similarities to migraine headaches, these prodromes hardly ever include aesthetic disturbances and are defined by prevomiting free signs of pallor, nausea or vomiting, stomach discomfort, sweating, and sleepiness. The typical recovery phase varies, ranging from minutes to 10 days, in all ages, with a median of 8 hrs in kids.

CVS episodes are defined by intense relentless nausea and repeated vomiting happening at least 4 times per hour for at the very least 1 hr [11]. The throwing up is typically projectile and contains bile, mucous, and, sometimes, blood. The latter could occur at any moment during the episode as an outcome of prolapse gastropathy, peptic esophagitis, and, much less typically, Mallory-Weiss rips from strong, repeated throwing up [17]. These patients can appear extremely debilitated during episodes. There are numerous signs and symptoms that generally go along with throwing up throughout CVS episodes. Abdominal discomfort, retching, anorexia, and nausea or vomiting are the most typical intestinal signs. Stomach discomfort throughout episodes (which occurs in 81% of kids and 58% of grownups) can be excruciating from time to time and could motivate unnecessary exploratory laparotomy. In a collection of 41 grownups prior to their diagnosis of CVS, 39% undertook various operations, 10 which were cholecystectomies [12], in futile attempts to cure reoccurring vomiting episodes.

Queasiness is reported by patients as one of the most relentless and traumatic sign. It is minimally eased by throwing up, usually declining just while sleeping or with sedation. Behaviors such as assuming a fetal position, withdrawing socially, alcohol consumption compulsively, taking prolonged warm or cool baths, and avoiding lights and noises prevail attempts to ease nausea or vomiting [16]. The nausea or vomiting is come with by autonomic dysfunction in CVS. The most usual free signs are lethargy and pallor. Various other autonomic symptoms consist of high temperature, flushing, salivating, looseness of the bowels, hypothermia, and hypertension. Less compared to fifty percent of the patients have migraine headache features, consisting of headache, photophobia, and phonophobia. Other signs throughout episodes include sensory hypersensitivity, vertigo, and sweating, which has been reported as a common function in grownups.

• Treatment:

Existing treatment for CVS can be separated into supportive treatment (during episodes), prophylactic therapy (to avoid episodes), and abortive treatment (to stop development from prodromal signs and symptoms to the throwing up phase). Methods for management of CVS during the interepisodic period consist of avoidance of identified triggers, way of life modifications, and emotional interventions. Although limited information exist on therapy outcomes in youngsters and adults with CVS, a current NASPGHAN agreement declaration has described standards for management of CVS in youngsters based mainly upon pediatric situation series [11].

Avoidance of known triggers, especially dietary triggers (eg, delicious chocolate, cheese, monosodium glutamate, nitrites, high levels of caffeine), could reduce the regularity of episodes. Way of life changes include evasion of anxiousness and excitement triggers in addition to energy-depleted states that can be generated by rest deprivation, fasting, disease, and physical overexertion. Those with high-energy demand or a background of fasting-induced episodes could take advantage of high-carbohydrate treats in between dishes, prior to physical exertion, and at going to bed [11]. Sometimes, tension

management methods with the aid of a psychologist could undermine the impacts of excitatory or adverse stress factors as well as lower the concern and expectancy of future episodes [20].

Daily use prophylactic medications is accorded to empiric therapy that is commonly used to treat other problems, including migraines, epilepsy, gastrointestinal dysmotility, and birth control (Table1). Prophylaxis needs to be considered in patients that have episodes that are regular (greater than 1 episode each month), severe (prolonged for even more than 3-5 days), incapacitating (linked with a hospital stay), or disabling (causing absence from college or work) [11]. Prophylaxis is likewise recommended for those that fall short a test of abortive therapy or encouraging actions. The utmost goal of treatment is to avoid attacks completely but, at the really least, to decrease the frequency, duration, or intensity of episodes.

Table 1. Prophylactic Pharmacotherapy [11], [18],[19],[21],[22],[26],[27].

Antimigraines
<ul style="list-style-type: none"> • Amitriptyline: start at 0.5 mg/kg and advance to 1–2 mg/kg per day QHS (adults 10–100 mg QHS). Monitor electrocardiogram QTc interval prior to starting. 1st choice >5 yrs old. SE: sedation, anticholinergic. • Propranolol: 0.25–1 mg/kg per day BID or TID (adults 40 mg BID). Monitor resting heart rate. SE: hypotension, bradycardia, fatigue. • Cyproheptadine: 0.25–0.5 mg/kg per day BID or TID. 1st choice <5 yrs old. SE: sedation, weight gain, anticholinergic. • Alternatives: nortriptyline, imipramine.
Anticonvulsants
<ul style="list-style-type: none"> • Phenobarbital: 2 mg/kg per day QHS. SE: sedation, cognitive impairment. • Valproate: 500–1,000 mg ER QHS. SE: somnolence, hepatotoxicity. • Carbamazepine: 5–10 mg/kg per day BID. SE: sedation, anticholinergic. • Alternatives: gabapentin, topiramate, levetiracetam, zonisamide.
Supplements
<ul style="list-style-type: none"> • L-carnitine: 50–100 mg/kg per day BID or TID (adults 660 mg–1 g BID or TID). SE: diarrhea, fishy body odor. • CoenzymeQ10: 10 mg/kg per day BID or TID.

ER=extended release;SE=side effects.

A family history of migraines is a strong indication (79%) of a favorable feedback to antimigraine therapy [11]. On top of that, linked signs of headache, photophobia, and phonophobia needs to make one take into consideration beginning anti-migraine prophylaxis with cyproheptadine, propranolol, or amitriptyline. In a limited pediatric situation series, efficiency was 39-61% for cyproheptadine, 52-65% for propranolol, and 67-- 81% for amitriptyline. The criterion for effectiveness was a greater-than-50% reduction in the frequency or severity of episodes. Cyproheptadine is the recommended selection for patients under 5 years old. The negative effects of daytime sedation could be reduced by solitary nighttime dosing as opposed to the common twice- or thrice-daily dosing routine. The side effects of enhanced appetite and excessive weight gain may make this a less positive option for overweight patients [11]. Propranolol is the second choice in youngsters of every ages based upon consensus guidelines [11]. It is contraindicated in asthmatics, has the negative effects of fatigue, and need to be accompanied by monitoring of the relaxing heart rate for possible bradycardia. Amitriptyline has been the most reliable prophylactic representative reported in pediatric and grown-up situation collection [11], [18]. Higher reaction rates have been observed with greater application (1 mg/kg/day or higher) in both pediatric and adult researches. A step-up technique in dosing with incremental boosts by 5-10 mg weekly is suggested for any ages to accomplish the wanted response while limiting negative effects [11], [19]. Nortriptyline and imipramine may be alternatives for those who experience side results from amitriptyline.

Other prophylactic representatives that have been used for CVS consist of phenobarbital, valproate, gabapentin, and carbamazepine (Table 2) [21]. Although they are specifically shown when spike and wave patterns are noted on electroencephalogram, they are significantly used in both migraine and CVS prophylaxis. Zonisamide and levetiracetam have shown modest (75%) response in grownups with CVS refractory to tricyclic antidepressant treatment. However,

moderate-to-severe side effects in 45% of patients in this collection limit their use in adults who fall short traditional prophylaxis [22]. Erythromycin has worked as a prokinetic representative, and low-dose estrogen birth control could be helpful in adolescent ladies who have catamenial CVS. One case collection documented a lowered frequency of CVS episodes with daily carnitine use [23]. Carnitine, a cofactor for long-chain fatty acid transportation into mitochondria, may assist CVS patients with metabolic or mitochondrial disorder [11]. Although no published data exist for its use, coenzyme Q10 has likewise been made use of as adjunctive treatment in CVS victims with presumed mitochondrial dysfunction.

Abortive treatment is intervention taken at the start of an episode or perhaps earlier throughout the prodromal stage, ideally to terminate the throwing up stage completely or minimize the period or severity of the episode. Abortive therapy ought to be taken into consideration for those who have erratic episodes that happen much less than as soon as each month and that prefer not taking treatment or those that have breakthrough episodes while on treatment [24]. As patients with unbending emesis are incapable to endure oral medication, these drugs typically need to be carried out parenterally or using rectal prep work.

The primary CVS abortive representatives consist of 5-HT 1B/1D agonists generally made use of for migraine headaches. Success rates are greater in those children with migraine-associated CVS, when made use of early in the episode, and in those with episodes less compared to 24 hrs long [18]. Sumatriptan carried out via oral, subcutaneous, or intranasal courses has a 51% effectiveness rate compared to a 65% effectiveness rate in headaches (Table 2) [18]. The feeling of substernal and neck burning hardly ever happens with intranasal administration. Use of zolmitriptan and frovatriptan in CVS is unscientific.

Table 2. Abortive Pharmacotherapy [11],[18],[19],[23],[24].

Antimigraines
<ul style="list-style-type: none"> Sumatriptan: 20 mg intranasally at episode onset and can repeat once or 25 mg orally once. SE: chest and neck burning, coronary vasospasm, headache. Alternatives: frovatriptan, rizatriptan, zolmitriptan.
Antiemetics
<ul style="list-style-type: none"> Ondansetron: 0.3–0.4 mg/kg per dose every 4–6 hours intravenously/orally. SE: headache, drowsiness, dry mouth. Alternatives: granisetron, aprepitant.
Sedatives
<ul style="list-style-type: none"> Lorazepam: 0.05–0.1 mg/kg per dose every 6 hours intravenously/orally. Useful adjunct to ondansetron. SE: sedation, respiratory depression. Chlorpromazine: 0.5–1 mg/kg per dose every 6 hours intravenously/orally. SE: drowsiness, hypotension, seizures. Diphenhydramine: 1.25 mg/kg per dose every 6 hours intravenously/orally. Useful adjunct to chlorpromazine. SE: hypotension, sedation, dizziness.
Analgesics
<ul style="list-style-type: none"> Ketorolac: 0.5–1 mg/kg per dose every 6 hours intravenously/orally. SE: gastrointestinal bleeding, dyspepsia. Alternatives: opioids.

Supportive care, which is used whenever intractable signs proceed during an episode that stops working to respond to abortive treatment, consists of intravenous liquids, nonstimulating setting, antiemetics, sedation, and analgesia [24]. Also handy could be intravenous fluids with high dextrose concentration (10%) and electrolytes, a silent, nonstimulating setting in a dark area, and induction of sleep via sedatives. If a combination of anti-emetics and benzodiazepines, in an effort to minimize nausea and aid the patient sleep via the worst component of their cycle, is not successful, analgesia is occasionally made use of first with nonsteroidal anti-inflammatory drugs and eventually with opioids, if required. Interepisodic nausea, anxiety, and stomach discomfort, common in adult CVS, could also gain from supportive care, consisting of antiemetics, antianxiety agents, and anesthetics.

Ondansetron, a 5-HT₃ antagonist, is mostly utilized as an antiemetic, with effectiveness rates around 62% [29]. More reliable at the greater dosing of 0.3-- 0.4 mg/kg each dosage, the side-effect profile has been exceptional, with couple of records of drowsiness, dry mouth, and headache (Table 2) [30]. Ondansetron generally decreases both nausea and vomiting but rarely terminates an episode. The addition of lorazepam offers sedation that may reduce intractable nausea. Sound sleep protects against vomiting throughout CVS episodes. When all else fails, intravenous administration of a mix of chlorpromazine plus diphenhydramine can create efficient sedation [25]. Previous experience recommends that phenothiazine antiemetics (D₂ antagonists) have bad efficiency in this disorder, even less compared to placebo reactions, suggesting that dopaminergic pathways are not included [11].

A placebo effect (70%) has been described from appointment alone prior to instituting treatment [26]. Knowledge of the medical diagnosis and effective therapies, decreases in stress and known triggers, in addition to a restricted diagnostic analysis eliminating worries of natural pathology might contribute to this placebo result. A limited trial of way of living modifications with the time duration of 1- 2 normal cycles may be considered an alternative for some.

4. CONCLUSION

CVS is an idiopathic functional vomiting disorder at first defined in kids that is increasingly recognized in grownups. Although documented pathophysiologic associations with migraine, mitochondrial conditions, and neuroendocrine abnormalities have been described in pediatric CVS, migraines, anxiety, and panic appear to be typical associations in adults that need further study. The natural history of CVS in children suggests that the majority of will outgrow this debilitating disorder with time, though some will transition to migraine headaches and even continue to suffer CVS as adults. Current therapy for CVS can be divided into supportive therapy (during episodes), prophylactic therapy (to avoid episodes), and abortive treatment (to prevent development from prodromal symptoms to the vomiting phase). Strategies for management of CVS during the interepisodic duration consist of avoidance of determined triggers, lifestyle modifications, and psychological interventions.

REFERENCES

- [1] Ertekin V, Selimoglu MA, Altınkaynak S. Prevalence of cyclic vomiting syndrome in a sample of Turkish school children in an urban area. *J Clin Gastroenterol* 2006; 40:896–898.
- [2] Pitts SR, Niska RW, Xu J, Burt CW. National Hospital Ambulatory Medical Care Survey: 2006 emergency department summary. *Natl Health Stat Report* 2008; 7:1–38.
- [3] Venkatesan T, Tarbell S, Adams K, McCanry J, Barribeau T, Beckmann K, et al. A survey of emergency department use in patients with cyclic vomiting syndrome. *BMC Emerg Med* 2010; 10:4–8.
- [4] Hejazi RA, Lavenbarg TH, Foran P, McCallum RW. Who are the nonresponders to standard treatment with tricyclic antidepressant agents for cyclic vomiting syndrome in adults? *Aliment Pharmacol Ther* 2010; 31:295–301.
- [5] To J, Issenman RM, Kamath MV. Evaluation of neurocardiac signals in pediatric patients with cyclic vomiting syndrome through power spectral analysis of heart rate variability. *J Pediatr* 1999; 135:363–366.
- [6] Namin F, Patel J, Lin Z, Sarosiek I, Foran P, Esmaeili P, McCallum R. Clinical, psychiatric and manometric profile of cyclic vomiting syndrome in adults and response to tricyclic therapy. *Neurogastroenterol Motil* 2007; 19:196–202.
- [7] Li BU, Murray RD, Heitlinger LA, Robbins JL, Hayes JR. Is cyclic vomiting syndrome related to migraine? *J Pediatr* 1999; 134:567–572.
- [8] Boles RG, Adams K, Li BU. Maternal inheritance in cyclic vomiting syndrome. *Am J Med Genet* 2005; 133A:71–77.
- [9] Zaki EA, Freilinger T, Klopstock T, Baldwin EE, Heisner KRU, Adams K, et al. Two common mitochondrial DNA polymorphisms are highly associated with migraine headache and cyclic vomiting syndrome. *Cephalalgia* 2009; 29:719–728.
- [10] Wang Q, Ito M, Adams K, Li BUK, Klopstock T, Maslim A, et al. Mitochondrial DNA control region sequence variation in migraine headache and cyclic vomiting syndrome. *Am J Med Genet* 2004; 131:50–58.

- [11] Li BUK, Lefevre F, Chelminsky GG, Boles RG, Nelson SP, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Consensus Statement on the Diagnosis and Management of Cyclic Vomiting Syndrome. *J Pediatr Gastroenterol Nutr.* 2008;47:379–393.
- [12] Fleisher DR, Gornowicz B, Adams K, Burch R, Feldman EJ. Cyclic vomiting syndrome in 41 adults: the illness, the patients, and problems of management. *BMC Med.* 2005;3
- [13] Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. In: Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE, editors. *The Functional Gastrointestinal Disorders–Rome II*. 2. McLean, VA: Degnon; 2000. pp. 318–319.
- [14] Prakash C, Staiano A, Rothbaum RJ, Clouse RE. Similarities in cyclic vomiting syndrome across age groups. *Am J Gastroenterol.* 2001;96:684–688.
- [15] Abell TL, Kim CH, Malagelada JR. Idiopathic cyclic nausea and vomiting—a disorder of gastrointestinal motility? *Mayo Clinic Proc.* 1988;63:1169–1175.
- [16] Li BUK, Fleisher DR. Cyclic vomiting syndrome: features to be explained by a pathophysiologic model. *Dig Dis Sci.* 1999;44:13S–18S.
- [17] Shepherd HA, Harvey J, Jackson A, Colin-Jones DG. Recurrent retching and gastric mucosal prolapse: a proposed prolapse gastropathy syndrome. *Dig Dis Sci.* 1984;29:121–128.
- [18] Sunku B, Li BUK. Cyclic vomiting syndrome. In: Guandalini S, editor. *Textbook of Pediatric Gastroenterology and Nutrition*. London, United Kingdom: Taylor and Francis Group; 2004. pp. 289–302.
- [19] Abell TL, Adams KA, Boles RG, Bousvaros A, Chong SK, et al. Cyclic vomiting syndrome in adults. *Neurogastroenterol Motil.* 2008;20:269–284.
- [20] Forbes D, Withers G, Silburn S, McKelvey R. Psychological and social characteristics and precipitants of vomiting in children with cyclic vomiting syndrome. *Dig Dis Sci.* 1999;44:19S–22S.
- [21] Gokhale R, Huttenlocher PR, Brady L, Kirschner BS. Use of barbiturates in the treatment of cyclic vomiting during childhood. *J Pediatr Gastroenterol Nutr.* 1997;25:64–67.
- [22] Clouse RE, Sayuk GS, Lustman PH, Prakash C. Zonisamide or levetiracetam for adults with cyclic vomiting syndrome: a case series. *Clin Gastroenterol Hepatol.* 2007;5:44–48.
- [23] Van Calcar SC, Harding CO, Wolff JA. L-carnitine administration reduces number of episodes in cyclic vomiting syndrome. *Clin Pediatr (Phila)* 2002;41:171–174.
- [24] Li BUK Cyclic vomiting syndrome. *Curr Treat Options Gastroenterol.* 2000;3:395–402.
- [25] Fleisher D. Empiric guidelines for the management of cyclic vomiting syndrome. Jul, 2008. Available at: <http://www.ch.missouri.edu/fleisher>.
- [26] Fleisher DR. Cyclic vomiting. In: Hyman PE, DiLorenzo C, editors. *Pediatric Gastrointestinal Motility Disorders*. New York, NY: Academy Professional Information Services; 1994. pp. 89–103.
- [27] Stout SC, Owens MJ, Nemeroff CB. Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment. *J Pharmacol Exp Ther.* 2002;300:1085–1092.
- [28] Basta-Kaim A, Budziszewska B, Jaworska-Feil L, Tetich M, Kubera M, et al. Inhibitory effect of imipramine on the human corticotropin-releasing-hormone gene promoter activity operates through a PI3-K/AKT mediated pathway. *Neuropharmacology.* 2005;49:156–164.
- [29] Li BUK, Murray RD, Heitlinger LA, Robbins JL, Hayes JR. Is cyclic vomiting syndrome related to migraine? *J Pediatr.* 1999;134:567–572.
- [30] Li BUK, Fleisher DR. Cyclic vomiting syndrome: features to be explained by a pathophysiologic model. *Dig Dis Sci.* 1999;44:13S–18S.